Thanh T Lam

US Patent:

20120136014, May 31, 2012

Filed:

Jun 2, 2011

Appl. No.:

13/151683

Inventors:

Zhiyong Chen - San Diego CA, US
Christopher J. Creghton - San Diego CA, US
Mark Cunningham - San Diego CA, US
John Finn - San Diego CA, US
Mark Hilgers - San Diego CA, US
Michael Jung - Los Angeles CA, US
Lucy Aguirre Kohnen - Cambridge MA, US
Thanh Lam - San Diego CA, US
Xiaoming Li - San Diego CA, US
Mark Stidham - San Diego CA, US
Les Tari - San Diego CA, US
Michael Trzoss - San Diego CA, US
Junhu Zhang - San Diego CA, US

Assignee:

TRIUS THERAPEUTICS, INC. - San Diego CA

International Classification:

A61K 31/517
C07D 401/14
C07D 239/72
A61P 31/10
A61P 33/00
A61P 31/04
A61P 29/00
C12N 9/99
C07D 417/14

US Classification:

51426621, 435184, 51426623, 5142664, 544284, 544291

Abstract:

The present disclosure provides compounds of Formula I:or a pharmaceutically acceptable salt thereof, wherein R, Rand Z are as described herein. The disclosure also provides pharmaceutical compositions thereof; and methods for inhibiting DHFR activity; and methods for treating cell proliferative diseases, autoimmune disease, inflammatory disease or bacterial, fungal or parasitic infection by administering a compound of Formula I.

US Patent:

20120238751, Sep 20, 2012

Filed:

Mar 14, 2012

Appl. No.:

13/496188

Inventors:

Daniel Bensen - Carlsbad CA, US
Zhiyong Chen - San Diego CA, US
John Finn - Encinitas CA, US
Thanh To Lam - San Diego CA, US
Suk Joong Lee - San Diego CA, US
Xiaoming Li - San Diego CA, US
Douglas W. Phillipson - Del Mar CA, US
Leslie William Tari - San Diego CA, US
Michael Trzoss - San Diego CA, US
Junhu Zhang - San Diego CA, US
Felice C. Lightstone - Fremont CA, US
Toan B. Nguyen - San Ramon CA, US
Sergio E. Wong - San Jose CA, US
Paul Aristoff - Dexter MI, US
Michael Jung - Los Angeles CA, US

Assignee:

TRIUS THERAPEUTICS, INC. - San Diego CA

International Classification:

C07D 487/04
C07D 471/10
C07D 487/08
C07D 471/08
C07D 487/10
C07D 491/048
C07D 491/056
C07D 487/14
C07D 471/14
C07D 471/04
C07D 498/04

US Classification:

540600, 544250, 544230, 544115, 544105, 544231, 544251

Abstract:

Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors.Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.

US Patent:

20130079323, Mar 28, 2013

Filed:

Sep 10, 2010

Appl. No.:

13/394985

Inventors:

Christopher J. Creighton - San Diego CA, US
Leslie William Tari - San Diego CA, US
Zhiyong Chen - San Diego CA, US
Mark Hilgers - San Diego CA, US
Thanh To Lam - San Diego CA, US
Xiaoming Li - San Diego CA, US
Michael Trzoss - San Diego CA, US
Junhu Zhang - San Diego CA, US
John Finn - San Diego CA, US
Daniel Bensen - Carlsbad CA, US

Assignee:

TRIUS THERAPEUTICS, INC. - San Diego CA

International Classification:

C07D 487/04
C07D 471/04
C07D 491/048
C07D 487/16
C07D 513/04

US Classification:

51421016, 544280, 5142651, 51425216, 5142342, 544117, 514249, 544265, 51426321, 514267, 544251, 51421021, 544250, 544279, 5142641, 51425202, 544238

Abstract:

Novel gyrase inhibitors and related compositions and methods are useful for impeding bacterial growth. Compounds of Formula (I), are disclosed: Formula (I), wherein Y is N or CH; Z is N or CR; Ris H, a substituted or unsubstituted hydrocarbyl residue (1-3C) containing 0-2 heteroatoms selected from O, S and N, or is an inorganic residue; L is O, S, NR, or CRR; Ris H or Calkyl; Rand Rare each independently H or Calkyl; Ris H, a hydrocarbyl residue (1-40C) containing 0-10 heteroatoms selected from O, S and N optionally substituted with an inorganic residue; Ris H, an inorganic residue, or a hydrocarbyl residue (1-30C) containing 0-12 heteroatoms selected from O, S and N and containing 0-10 inorganic residues, wherein Rand Rtogether may join to form a fused ring; and Ris selected from the group consisting of H, Calkyl, Calkenyl, Calkynyl, halo Calkyl, halo Calkenyl, halo Calkynyl, Chydroxyalkyl, Calkyl chloride, Calkenyl chloride, and Calkynyl chloride; or a pharmaceutically-acceptable salt, ester, or prodrug thereof.

US Patent:

20220257787, Aug 18, 2022

Filed:

Apr 21, 2021

Appl. No.:

17/236722

Inventors:

- San Diego CA, US
Daniel C. BENSEN - Carlsbad CA, US
Allen BORCHARDT - San Diego CA, US
Thomas P. BRADY - San Diego CA, US
Zhi-Yong CHEN - La Jolla CA, US
Jason COLE - San Diego CA, US
Simon DOEHRMANN - San Diego CA, US
Wanlong JIANG - San Diego CA, US
Thanh LAM - San Diego CA, US
Alain NONCOVICH - La Jolla CA, US
Leslie W. TARI - Solana Beach CA, US

International Classification:

A61K 47/68

Abstract:

Compositions and methods for the treatment of viral infections include conjugates containing inhibitors of viral neuraminidase (e.g., zanamivir, peramivir, or analogs thereof) linked to an Fc monomer, an Fc domain, and Fc-binding peptide, an albumin protein, or albumin-binding peptide. In particular, conjugates can be used in the treatment of viral infections (e.g., influenza viral infections).

US Patent:

20210220478, Jul 22, 2021

Filed:

Mar 5, 2021

Appl. No.:

17/194093

Inventors:

- San Diego CA, US
Daniel C. BENSEN - Carlsbad CA, US
Allen BORCHARDT - San Diego CA, US
Thomas P. BRADY - San Diego CA, US
Zhi-Yong CHEN - La Jolla CA, US
Jason COLE - San Diego CA, US
Simon DOEHRMANN - San Diego CA, US
Wanlong JIANG - San Diego CA, US
Thanh LAM - San Diego CA, US
Alain NONCOVICH - La Jolla CA, US
Leslie W. TARI - Solana Beach CA, US

Assignee:

Cidara Therapeutics, Inc. - San Diego CA

International Classification:

A61K 47/68
A61P 31/16

Abstract:

Compositions and methods for the treatment of viral infections include conjugates containing inhibitors of viral neuraminidase (e.g., zanamivir, peramivir, or analogs thereof) linked to an Fc monomer, an Fc domain, and Fc-binding peptide, an albumin protein, or albumin-binding peptide. In particular, conjugates can be used in the treatment of viral infections (e.g., influenza viral infections).

US Patent:

20170369498, Dec 28, 2017

Filed:

Jul 7, 2017

Appl. No.:

15/643760

Inventors:

- North Wales PA, US
- LIVERMORE CA, US
John Finn - Encinitas CA, US
Thanh T. Lam - San Diego CA, US
Suk J. Lee - San Diego CA, US
Xiaoming Li - San Diego CA, US
Douglas W. Phillipson - Del Mar CA, US
Leslie W. Tari - San Diego CA, US
Michael Trzoss - San Diego CA, US
Junhu Zhang - San Diego CA, US
Felice C. Lightstone - Fremont CA, US
Toan B. Nguyen - Marlborough CA, US
Sergio E. Wong - Tracy CA, US
Paul Aristoff - Dexter MI, US
Michael Jung - Los Angeles CA, US

Assignee:

Merck Sharp & Dohme Corp. - North Wales PA
LAWRENCE LIVERMORE NATIONAL SECURITY, LLC - LIVERMORE CA

International Classification:

C07D 487/04
C07D 487/14

Abstract:

Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors.Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.

US Patent:

20170037059, Feb 9, 2017

Filed:

Sep 16, 2016

Appl. No.:

15/267978

Inventors:

- Rahway NJ, US
Leslie William Tari - San Diego CA, US
Zhiyong Chen - San Diego CA, US
Mark Hilgers - San Diego CA, US
Thanh To Lam - San Diego CA, US
Xiaoming Li - San Diego CA, US
Michael Trzoss - San Diego CA, US
Junhu Zhang - San Diego CA, US
John Finn - San Diego CA, US
Daniel Bensen - Carlsbad CA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 519/00
C07D 471/16
C07D 487/04

Abstract:

Novel gyrase inhibitors and related compositions and methods are useful for impeding bacterial growth. Compounds of Formula (I), are disclosed: Formula (I), wherein Y is N or CH; Z is N or CR; Ris H, a substituted or unsubstituted hydrocarbyl residue (1-3C) containing 0-2 heteroatoms selected from O, S and N, or is an inorganic residue; L is O, S, NR, or CRR; Ris H or Calkyl; Rand Rare each independently H or Calkyl; Ris H, a hydrocarbyl residue (1-40C) containing 0-10 heteroatoms selected from O, S and N optionally substituted with an inorganic residue; Ris H, an inorganic residue, or a hydrocarbyl residue (1-30C) containing 0-12 heteroatoms selected from O, S and N and containing 0-10 inorganic residues, wherein Rand Rtogether may join to form a fused ring; and Ris selected from the group consisting of H, Calkyl, Calkenyl, Calkynyl, halo Calkyl, halo Calkenyl, halo Calkynyl, Chydroxyalkyl, Calkyl chloride, Calkenyl chloride, and Calkynyl chloride; or a pharmaceutically-acceptable salt, ester, or prodrug thereof.

US Patent:

20160222015, Aug 4, 2016

Filed:

Sep 10, 2014

Appl. No.:

15/021314

Inventors:

- Rahway NJ, US
- Livermore CA, US
Zhiyong Chen - San Diego CA, US
Junhu Zhang - San Diego CA, US
Douglas Phillipson - Del Mar CA, US
Suk Joong Lee - San Diego CA, US
Michael Trzoss - San Diego CA, US
Daniel Bensen - Carlsbad CA, US
Xiaoming Li - San Diego CA, US
Min Teng - San Diego CA, US
Voon Ong - San Diego CA, US
Allen John Borchardt - San Diego CA, US
Thanh To Lam - San Diego CA, US
Felice C. Lightstone - Fremont CA, US
Sergio E. Wong - Tracy CA, US
Toan B. Nguyen - Marlborough MA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
Lawrence Livermore National Security, LLC - Livermore CA

International Classification:

C07D 487/04
C07F 9/6561
C07D 491/16

Abstract:

Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.